Paradigm Biopharmaceuticals Ltd (ASX:PAR) has caught investor attention this morning with its shares jumping 75% following the publication of a peer-reviewed journal of the potential of Pentosan Polysulfate Sodium (PPS).
PPS is an anti-inflammatory and an anti-histamine with biological characteristics, and has been used in humans for more than 60 years.
The review covered PPS to treat bone marrow edema, a growing market opportunity Paradigm has a focus on.
Company Name · Code · Last · Change · Volume
Byte Power Group Ltd · BPG · $0.002 · 100% · 111,229
Paradigm Biopharmaceuticals Ltd · PAR · $0.500 · 75.44% · 1,387,684
White Cliff Minerals Ltd · WCN · $0.004 · 33.33% · 200,000
First Growth Funds Ltd · FGF · $0.009 · 28.57% · 36,035,992
Genera Biosystems Ltd · GBI · $0.160 · 23.08% · 55,889
Sumatra Copper & Gold Ltd · SUM · $0.016 · 23.08% · 145,399
Diatreme Resources Ltd · DRX · $0.012 · 20% · 265,424
Valor Resources Ltd · RMI · $0.006 · 20% · 7,500
Analytica Ltd · ALT · $0.006 · 20% · 1,500,000
Valor Resources Ltd · VAL · $0.031 · 19.23% · 26,649,287